Cellular factors that bind to cis sequences in the human papillomavirus 16 (HPV-16) upstream regulatory region (URR) positively and negatively regulate the viral E6 and E7 oncogene promoter, P97. DNase I footprinting has revealed the binding of cellular proteins to two previously undetected cis elements overlapping and 39 of the transcription-initiation site of the P97 promoter. Mutations within homologous motifs found in both of these cis elements abolished their negative function in vivo and the binding of the same cellular complex in vitro. This factor was identified as YY1 by complex mobility and binding specificity in comparison with vaccinia virusexpressed, purified recombinant YY1 protein and by antigenic reactivity with YY1 antisera. Cis mutations in the 'initiator' YY1 site activated the P97 promoter in vivo and in vitro. P97 was also activated threefold in vitro by depletion of endogenous YY1 with wild-type, but not mutant, YY1 oligonucleotides from the IgH kappa E39 enhancer. Furthermore, increasing concentrations of exogenous, purified recombinant YY1 repressed wild-type P97 transcript levels by up to threefold, but did not influence the P97 promoter mutated in the 'initiator' YY1 site. Thus, the promoter-proximal YY1 site was not necessary for correct transcription initiation at the P97 promoter, but was found to be required for downregulation of P97 transcription in vivo and in vitro. In contrast to other viral and cellular promoters, where YY1 is thought to function as a positive transcription-'initiator' factor, HPV-16 P97 transcription is downregulated by YY1 from a critical motif overlapping the transcription start site.
INTRODUCTION
Human papillomaviruses (HPVs) are small DNA tumour viruses that infect, persist in and cause proliferative lesions in the epithelial cells of the skin, ectoderm-derived mucosae and their adnexa. Mucosal HPV types are associated with the majority of carcinomas of the uterine cervix, many anogenital cancers and approximately 25 % of head and neck cancers (reviewed by Psyrri & DiMaio, 2008) . HPV persistence is dependent on tightly regulated expression of viral transforming genes (E6 and E7) and limiting levels of critical replication factors (such as E1) (Hebner & Laimins, 2006) . However, a complete understanding of the mechanisms that maintain latent human papillomavirus (HPV) infection or of cellular factors that may restrict early papillomaviral gene expression in the basal epithelium is limited (Thierry, 2009 ). The HPV-16 transforming proteins, E6 and E7, are transcribed from a single major early promoter, P97. The HPV-16 P97 promoter is regulated by upstream cis elements that interact with multiple cellular and viral transcription factors, such as TEF-1 (Ishiji et al., 1992) , AP-1 (Cripe et al., 1990) , AP-2, PEF-1 (Cuthill et al., 1993) , NF-1/CTF (Gloss et al., 1987) and the HPV E2 gene products (Cripe et al., 1987; Lace et al., 2008a; Soeda et al., 2006) . Deletion mutagenesis of the HPV-16 regulatory region has indicated that, in addition to the TEF-1-dependent 63 nt proximal enhancer fragment (PE), other cis-acting sequences influence early gene expression (Cripe et al., 1990; Ishiji et al., 1992; Lace et al., 2008b) ; however, the role of cis sequences spanning the P97 initiation site in the regulation of HPV-16 transcription and the identity of cellular factors interacting with them has remained poorly defined. The low basal activity of the HPV-16 promoter in keratinocytes suggests that one or more nuclear proteins downregulate P97 promoter activity by interacting with the HPV-16 regulatory cis sequences. Downregulation of E6-E7 expres-sion from the P97 promoter by this mechanism would be expected to contribute to virus latency. This study focuses on the identification of a cellular transcription factor responsible for the downregulation of transcription from the HPV-16 major early promoter.
The ubiquitous cellular factor YY1 (UCRBP, d, NF-E1, CF1 or NMP-1) is thought to play a critical role in tumorigenesis (Gordon et al., 2006) and HPV infection (Baritaki et al., 2007) and has been shown to function as both a positive (Riggs et al., 1993; Satyamoorthy et al., 1993; Mills et al., 1994) and a negative (Lee et al., 1992; Liu et al., 1994; Margolis et al., 1994; Montalvo et al., 1995) regulator of cellular and viral gene expression. YY1 is a zinc fingerbinding protein related to the Drosophila Krüppel repressor family that was originally defined as a dual positive and negative regulator of the same adeno-associated virus (AAV) P5 promoter, depending on its binding position . YY1 binding to a site located 60 bp upstream represses P5 promoter activity, whereas its binding to an initiator-like site overlapping the P5 transcription start site was observed to activate the AAV P5 (+1) promoter in vitro . YY1 has since been identified as a dual regulator of other key cellular promoters Weill et al., 2003) and other examples of this dual functional role among transcription factors have also been documented (reviewed by Roberts & Green, 1995) . YY1 has also been characterized as an initiator of vaccinia virus late gene expression by binding to the I1-L start site (Broyles et al., 1999) .
The role of YY1 in the regulation of HPV early gene expression has been supported by results suggesting that the major early promoters (MEPs) of HPV-18 (Bauknecht et al., 1992) and HPV-11 (Ralph et al., 2006) are repressed by YY1 binding to distal sites upstream of the MEPs. It has also been shown that extrachromosomal or integrated HPV-16 DNA isolated from malignant cervical biopsies contains mutated or deleted YY1 sites upstream of the P97 start site (May et al., 1994; Schmidt et al., 2001) , resulting in increased P97 transcription, origin of replication (ori) function, initial plasmid amplification and virus immortalization capacity (Lace et al., 2009) . It has also been suggested that YY1 bound to several upstream motifs targets transcriptional activators such as AP-1 (O'Connor et al., 1996) . YY1 also appears to exert both positive and negative effects on the cutaneous HPV-8 E6 promoter, depending on its binding position (Pajunk et al., 1997) . YY1 may also act as an initiator of a putative transcription start site, upstream and independent of the early gene promoter, E6-E7, in HPV-16 (Tan et al., 2003) . However, in contrast to heterologous viral promoters where YY1 clearly functions as an initiator of transcription, e.g. the AAV P5(+1), we demonstrate that downregulation of the HPV-16 E6-E7 promoter requires YY1 binding to a critical motif adjacent to the P97 transcription start site.
METHODS
Plasmid constructs. The wild-type P97-(nt 6530 to +153) cat reporter was synthesized by PCR amplification followed by digestion with BamHI and HindIII and insertion into a pUC 18-cat vector. Nucleotide substitutions in the P97 cis elements were introduced by PCR (Ishiji et al., 1992) , followed by digestion with SphI/HindIII or AgeI/HindIII and insertion into the P97 cat parent. The HPV-16 W12E plasmid (GenBank accession no. AF125673) was a gift from P. Lambert, McArdle Laboratory for Cancer Research, Madison, WI, USA (Flores & Lambert, 1997) . The pUC-based precursors of the HPV-16 genomic plasmids were digested with BamHI and recircularized as described previously (Lace et al., 2008b) . YY1 expression plasmids were gifts from J. Flanagan, University of Iowa, Iowa City, IA, USA. The pCG-neo plasmid was constructed by using the BamHIHindIII fragment from SV2-neo and the pCG backbone (Ushikai et al., 1994) . The P97 G-free plasmids were synthesized via a single round of PCR. The HPV-16 G-free PCR products extend to nt +111, incorporating G-to-C transversions at nt +101 and +106. These nucleotide substitutions were found to ensure that P97 initiated Gfree transcripts. The PCR products were digested with EcoRI and PmlI and linked to a 380 nt G-free cassette, G-free 380 (a gift from R. Cortese, CEINGE, Naples, Italy). The Ad MLP G-free110 plasmid was a gift from R. Roeder, Rockefeller University, New York, NY, USA. The TM-YY1 expression plasmid was constructed by digestion of UCRBP (YY1) cDNA plasmid (Flanagan et al., 1992) with NcoI and XbaI and insertion into the TM-1 vector (Moss, 1991) . All PCRgenerated clones were sequenced by using an automated ABI sequencer. All plasmids were column-purified (Promega).
Cells and transfections. HeLa and HaCaT (a gift from N. Fusenig, DFKZ, Heidelberg, Germany) cell lines were cultured as described previously (Cripe et al., 1990) . SCC13 cells were cultured as described elsewhere (Lace et al., 2008b) . HeLa cells were transfected in duplicate with 1.5 mg reporter construct DNA per 35 mm well by calcium precipitation (Cripe et al., 1987) , whilst HaCaT cells (Boukamp et al., 1988) were transfected with 9 mg reporter construct per 100 mm dish by lipofection (Life Technologies) as described previously (Ishiji et al., 1992) . Up to 40 mg recircularized HPV-16 genome was transfected into HeLa cells (which do not support HPV replication) prior to RNA harvest and analysis by RNase protection as described elsewhere (Ushikai et al., 1994) .
YY1 protein expression. The recombinant vaccinia virus (Moss, 1991) expressing the YY1 protein was isolated as described previously (Ushikai et al., 1994) . In vitro-translated YY1 was synthesized by using the UCRBP (YY1) plasmid (Flanagan et al., 1992) as a transcription template and the RNA translated in rabbit reticulocyte lysate (Promega) according to the manufacturer's protocol.
Extraction and purification of recombinant YY1 from vaccinia virus-infected cells. Confluent HeLa cultures were infected as described previously (Ushikai et al., 1994) . Cells were harvested and washed with 150 mM NaCl/10 mM Tris/HCl 14 h after infection. The recombinant YY1 protein was then extracted by using a previously described ammonium sulfate protocol (Cripe et al., 1990) where both nuclear and cytoplasmic fractions were collected. The protein was then purified by passage over a DEA-cellulose column and elution in 600-800 mM KCl as described previously (Ushikai et al., 1994) , followed by three cycles of adsorption and elution from a DNA affinity column. The affinity column was constructed with 15 mg biotinylated PCR product, generated by amplification of the Moloney murine leukemia virus (MLV) upstream conserved region (UCR) element (Flanagan et al., 1992) that was isolated on a 200 ml streptavidin-agarose bed. Purified affinity fractions were then concentrated approximately sevenfold by using a Centricon ultrafiltration column (molecular mass cut-off of 30 kDa; Amicon). The protein was then dialysed to a final KCl concentration of 50 mM in a micro-collodium bag (Sartorius). The purity of the YY1 preparation was checked by Western blotting with YY1 antisera, which revealed an enriched protein with a characteristic apparent size (kDa) consistent with YY1 (data not shown).
Mobility-shift assays. Electrophoretic mobility-shift assays were performed as described previously (Ishiji et al., 1992) . YY1 binding reactions included 5 % (v/v) glycerol, 0.2 mM EDTA, 1.0 mM dithiothreitol (DTT), 1.0 mM MgCl 2 , 20 mM Tris (pH 7.6), 30 nM BPV-1 E2 site # 10 oligonucleotide (59-GGTCAAACCGTCTTCGGT-GCTC) and 30 nM pdI : dC (Amersham) as non-specific competitors, 0.2 mg BSA ml 21 and 50 mM KCl as well as 15 000 c.p.m. gel-purified, [c-
32
P]dATP-labelled oligonucleotide probes. For antibody supershifts, YY1 binding was followed by incubation with pre-immune serum or polyclonal YY1 antiserum (J. Flanagan, University of Iowa) for 15-30 min on ice before loading onto a 6 % (w/v) polyacrylamide gel.
In vitro transcription assays. In primer-extension assays, initial transcription reactions were incubated for 45 min at 25 uC with 200-400 ng HPV-16 cat plasmid template in the presence of 9 ml in vitro transcription assay buffer, 3 mM MgCl 2 , 0.2 ml RNAguard (Amersham), 10 ml pretested HeLa whole-cell extract (Xiao et al., 1991) , 5 mM cold rNTPs and 0.3 ml [a-32 P]rUTP (15 pmol), then stopped with 0.2 % SDS. Following phenol/chloroform extraction and ethanol precipitation, the cDNA was then hybridized at 45 uC for 1.5 h with 4000 c.p.m. 59-labelled cat (reverse) primer (59-TTAGCTCCTGAAAATCTCGCC) before incubation at 37 uC for 1 h with 10 U avian myeloblastosis virus reverse transcriptase (Amersham), 20 mM Tris (pH 8.0), 10 mM MgCl 2 , 5 mM DTT, 0.33 mM dNTPs and 50 mg actinomycin D ml 21 . After ethanol precipitation, primer-extension reactions were then run on a 6 % (w/v) polyacrylamide gel in TBE buffer. G-free in vitro transcriptions, using 200 ng P97 G-free templates per reaction, were performed with HeLa nuclear extracts (Promega) as described previously (Ushikai et al., 1994) . In vitro competitions were performed with a known YY1-binding motif from the kappa-immunoglobulin enhancer (IgH kappa E39) (Park & Atchison, 1991) . Transcripts were visualized on X-ray film and quantified by densitometric scanning.
DNase I footprinting and Southern blotting. A DNA-footprinting probe was PCR-amplified from an HPV-16 cat plasmid template containing HPV-16 nt 7453 to +191 linked to the cat gene. An unlabelled HPV-16 primer (59-TGCATATTTGGCATAAGGTTT-AAACTT) and [c-32 P]dATP 59-labelled cat (reverse) primer were used to amplify the 360 nt HPV-16 probe template. Footprints were generated with 20 000 c.p.m. probe, 10 ml crude HaCaT nuclear extract, 30 nM pdI : dC and 30 nM BPV-1 E2 site #10 oligonucleotide as non-specific competitors, and 1.25 ng DNase I (Amersham) in 20 mM Tris (pH 7.6), 5 % (v/v) glycerol, 0.2 mM EDTA, 50 mM KCl, 1 mM DTT and 1 mM MgCl 2 . The footprinting reactions were incubated at 30 uC for 30 min as described previously (Cripe et al., 1990) and resolved on an 8 % (w/v) polyacrylamide gel. A total of 3 mg religated HPV-16 DNA was transfected into SCC13 cells with Effectene (Qiagen). Total DNA was then isolated from transfected cells (QIAamp DNA Blood kit; Qiagen) 5 days post-transfection and 4 mg of each DNA sample was digested with DpnI and linearized with BamHI before Southern blotting as described previously (Lace et al., 2008b) .
RESULTS
Cellular factors bind to the HPV-16 P97 transcription start site region DNase I footprinting was performed with HPV-16 sequences spanning the P97 start site and unfractionated nuclear extracts from a human keratinocyte cell line (HaCaT). Cellular proteins formed footprints over two distinct regions, one overlapping (nt +82 to +113) and the other 39 (nt +129 to +157) of the P97 start site (Figs 1 and  2 ). These previously unidentified footprints, 'fp X' and 'fp Y', fell within two homologous regions that could potentially modulate initiation of P97 transcription ('initiators' Inr I and Inr III, respectively). Having demonstrated cellular protein interaction with promoter-proximal HPV-16 Inr elements, we examined the identity of cellular transcription factors binding to these cis elements and their role in the regulation of HPV-16 transcription.
A cellular factor bound to the promoter-proximal HPV-16 P97 Inr elements is indistinguishable from YY1
A sequence comparison of the two cis-acting Inr elements encompassed by cellular footprints 'fp X' and 'fp Y' revealed a homologous motif, CCA(C/A)A (Fig. 1) . Several additional homologous HPV-16 motifs located upstream of the P97 start site were examined and found to be important for the negative function of distal 'silencer' elements in a parallel study (M. J. Lace, unpublished data). We sought to identify the cellular factors forming specific complexes with these homologous Inr motifs in mobilityshift assays by using fractionated keratinocyte (HaCaT) nuclear extracts and the oligonucleotides listed in Fig. 1 .
We compared the homologous motifs in HPV-16 with recognition sites of known negative-regulatory transcription factors, revealing a match with the core of the degenerate consensus site (CCAT) for the ubiquitous transcription factor YY1 (Lee et al., 1992) (Fig. 1) . A cellular factor formed indistinguishable, specific complexes with both of the homologous HPV-16 Inr I and Inr III motifs and the YY1 control sequence, 'UCR wt', from the MLV long terminal repeat (LTR) (Flanagan et al., 1992) (Fig. 2b, lanes 1, 3 and 5) . Mutations within the homologous Inr motifs and the control YY1-binding site abolished formation of this complex (Fig. 2b , lanes 2, 4 and 6). Vaccinia virus-expressed YY1 also formed a complex with the UCR probe that is indistinguishable from those formed on the HPV-16 Inr motifs (Fig. 2b , compare lane 7 with 9 and 11). Mutations that disrupted binding of the cellular factor to the Inr cis elements also abolished recombinant YY1 binding (Fig. 2b, lanes 8, 10 and 12) . These results show that YY1 binding to promoter-proximal cis elements contributes to the formation of cellular footprints overlapping and 39 of the P97 start site.
Dissociation constants were determined as described previously (Ushikai et al., 1994) for in vitro-translated YY1 binding to the promoter-proximal HPV-16 Inr YY1 sites (Fig. 2c) . The addition of unlabelled wild-type HPV-16 Inr competitor oligonucleotides to YY1 complexes formed on the MLV UCR motif specifically depleted the YY1/UCR complex (Fig. 2c, lanes 1-4 and 8-10) . Addition of the mutant competitors (Fig. 2c , lanes 5-7 and 11-13), however, did not deplete the YY1 complex as efficiently as the wild-type competitors. The approximate dissociation constants for YY1 binding to the HPV-16 Inr I, Inr III and UCR control sites were quantified by densitometric scanning of two or three independent experiments and found to be 5, 3 and 15 nM, respectively.
A polyclonal antibody directed against the C terminus of the YY1 protein was used to test the antigenicity of the cellular complexes formed with the promoter-proximal cisacting motifs. Whilst the pre-immune serum did not react with either of the complexes (Fig. 2d, lanes 4 and 8) , the YY1 antiserum produced a supershifted complex with the cellular factor bound to each of the HPV-16 cis elements (Fig. 2d, lanes 3 and 7) . Taken together, these results demonstrate that the cellular factor binding to negative cisacting motifs in the HPV-16 regulatory region is indistinguishable from YY1 by complex mobility, binding specificity and antigenicity.
YY1 downregulates the HPV-16 P97 promoter from the Inr I site in vivo Mutations in the homologous Inr motifs were introduced into the native HPV-16 P97 promoter CAT construct and assayed in transient transfections in both the keratinocytederived cell line HaCaT and a cervical carcinoma cell line (HeLa), in which endogenous YY1 has been shown to function as a transcriptional repressor of other viral promoters . Interestingly, mutation of the homologous Inr III site (Fig. 3a, clone c) had little effect in the context of the intact, 1 kb HPV-16 promoter. Mutation of the Inr I motif, however, resulted in an increase in CAT activity in both cell types (clone b), indicating that YY1 downregulates P97 promoter activity from the pivotal Inr I site.
To verify that the Inr I YY1-binding site influenced the levels of correctly initiated transcripts from the P97 start site, mutation of the Inr I YY1-binding site in the HPV-16 promoter was also shown to increase the steady-state HPV-16 P97 mRNA levels by 4.3-fold in an RNaseprotection assay (Fig. 3b, lanes 1-2, template a) . A comparable increase in transcription was also detected in constructs that included the Inr I mutation in the intact 7.9 kb HPV-16 genome (Fig. 3b, lanes 3-4,  template b) ; this discrete mutation (Inr mut 14) similarly abolished YY1 binding in vitro and activated P97 transcription. As in all RNase-protection assays in YY1 repression of HPV-16 early gene transcription this study, P97 transcription from the replicationcompetent HPV-16 W12E plasmid was measured in the absence of detectable viral plasmid amplification (data not shown). However, the Inr I mutation did not affect HPV plasmid replication in a keratinocyte cell line, as measured by Southern blotting (Fig. 3b, lanes 5-6) . Overexpression of wild-type YY1 was shown to reduce P97 promoter activity in vivo, whereas addition of the defective, YY1-reverse expression plasmid had little effect (Fig. 3c) . Mutation of the P97 Inr I YY1 site relieved the negative effects of endogenous levels of YY1. Addition of the YY1 wt plasmid, expressing high levels of exogenous 32 P-Labelled PCR-generated HPV-16 DNA (nt 7736 to +191) and crude HaCaT nuclear extract were included in DNase I reactions in lanes 2 and 3, forming protected areas, footprint fp'X' (nt +82 to +113) and footprint fp'Y' (nt +129 to +157). Lane 1 is the control reaction without nuclear extract. Arrows indicate hypersensitivity sites. (b) Oligonucleotides used as probes and competitors in these mobility-shift assays are listed in Fig. 1 The pre-immune serum (P) was included as a negative control. ns, Non-specific bands.
YY1, however, had no effect on this mutated HPV-16 target (Fig. 3c) . Taken together, these results demonstrate that downregulation of HPV-16 P97 transcription in vivo requires YY1 binding to a motif overlapping the P97 start site.
YY1 binding to the P97 start site is required for downregulation of the HPV-16 promoter in vitro
Having shown that the YY1-binding sites are involved in P97 downregulation in vivo, we then examined the effect of The effect of mutation of the promoter YY1 site on P97 activity was analysed in the context of the 1 kb HPV-16 promoter (template a) and the whole 7.9 kb HPV-16 genome (template b) in RNase-protection assays using HeLa cells. HPV-16 replication in transfected SCC13 cells was detected as BamHI-linearized, DpnI-resistant 7.9 kb DNA by Southern blotting. An SV40-cat plasmid was cotransfected as an internal control. The nucleotide substitution for this mutation (Inr mutant 14) was position 91-92, AA to CC (Fig. 1) . (c) The P97 cat reporter was cotransfected with equivalent amounts of pCG neo or the YY1 expression plasmids generating functional (YY1) or inactive (YY1-rev) protein. These values represent averages of three independent CAT assays.
YY1 on P97 transcription in vitro, using transcriptioncompetent HeLa extracts (Fig. 4a) . Primer extensions were performed with the same native P97 templates that were tested in vivo (Fig. 2a, b) , including those carrying mutations in the Inr YY1-binding sites (clones b, c and d in Fig. 2a) . Consistent with the results seen in vivo, mutation of the Inr III YY1 site had no effect (Fig. 4a, lane   9 ), whereas mutation of the promoter-proximal YY1-binding site (Inr I) increased in vitro P97 transcription in a primer-extension assay (Fig. 4a, lane 6) . G-free P97 templates were also constructed and tested in a more stringently defined in vitro system to ensure that the transcription levels measured were indeed initiated from the HPV-16 P97 start site. Mutation of the Inr I YY1-binding site also elevated levels of P97 transcripts threefold in these experiments (Fig. 4b, lane 2) .
Vaccinia virus-expressed YY1 was titrated against the wildtype P97 G-free construct and its corresponding mutant in the promoter-proximal YY1-binding site (Inr I) (Fig. 4c) .
Transcription from the wild-type P97 template was repressed by at least twofold upon the addition of purified YY1 protein (Fig. 4c, lane 3) , whilst mutation of the Inr I YY1 site rendered the HPV-16 promoter unresponsive to YY1 repression in parallel (Fig. 4c, lanes 4-6) , indicating that the promoter-proximal (Inr I) YY1 site is necessary for YY1-mediated repression in vitro.
To verify that endogenous YY1 was responsible for P97 downregulation in these experiments, we used an unrelated high-affinity YY1-binding motif (Fig. 1, oligo h ) from the 39 kappa immunoglobin enhancer (Park & Atchison, 1991) as an in vitro competitor (Fig. 4d) . Addition of the wildtype YY1-binding site resulted in a threefold increase in P97 transcription, whereas the YY1 mutant competitor (Fig. 1 , oligo i) had no effect (Fig. 4d , compare lanes 2 and 3 with 4 and 5). Either mutation of the Inr I motif or depletion of endogenous YY1 by addition of an unrelated YY1-binding competitor sequence resulted in an identical threefold increase in P97 transcription in G-free transcription assays (Fig. 4d ) and primer extensions (Fig. 4e, lanes  1-4) . Therefore, the binding of endogenous YY1 to the target sequences is required for P97 promoter repression in vitro. In contrast, the same YY1 competitor was able to reduce transcription from the initiator-dependent AAV P5 (+1) promoter in parallel primer-extension assays (Fig. 4e , lanes 5 and 6). These results demonstrate that YY1 binding to the promoter-proximal YY1 site is necessary for downregulation of P97 transcription in vitro -a mechanism distinct from YY1-dependent initiation of AAV (P5) transcription.
DISCUSSION
In summary, this study has demonstrated that, contrary to the dual positive/negative YY1 regulation of other promoters, cellular factor YY1 downregulates the HPV-16 P97 promoter in in vitro and in vivo assays by binding to a previously undefined cis motif located immediately upstream of the P97 start site. In contrast to previous studies, we examined YY1-mediated modulation of HPV-16 transcription not only with promoter fragments, but also with viral constructs capable of expressing endogenous levels of the entire complement of viral genes from an intact genomic plasmid.
YY1 downregulation of HPV transcription
Multiple functional YY1 sites have been identified in HPV regulatory sequences (this study), in HPV-18 (Bauknecht et al., 1992) and in extrachromosomal (May et al., 1994) and integrated (Schmidt et al., 2001 ) HPV-16 DNA isolates from clinical cervical carcinoma biopsies. Mutations or deletions of multiple HPV/YY1 sites in defined intratypic HPV-16 variants relieve downregulation of P97 promoter activity and plasmid replication (Hubert, 2005) and contribute to a greater potential for the altered HPV genome to transform primary keratinocytes in culture (Lace et al., 2009 ). These observations indicate that YY1-mediated regulation of early viral gene expression in HPVimmortalized keratinocytes is a conserved mechanism. The nature of this mechanism, however, is only partially defined.
This study demonstrated that YY1 binding to a promoterproximal site is sufficient to downregulate HPV-16 E6-E7 transcription, but does not exclude the possibility of cooperative interaction with YY1 bound to additional sites in the HPV-16 promoter. The cooperative interaction between multiple repressor-binding sites and their cognate factor has been described in other systems; for example, the Drosophila Krüppel-like repressor eve has been shown to repress the ubx promoter by binding to a pivotal highaffinity site and cooperating with eve bound to additional distal sites (TenHarmsel et al., 1993) via displacement of the trans-activating factor zeste. YY1 has been shown to displace transcription activators such as serum response factor (SRF) at the c-fos SRE (Gualberto et al., 1992) and mammary growth factor (MGF) (Meier & Groner, 1994) ; however, YY1 displacement of activators bound to the HPV-16 E6-E7 promoter has yet to be demonstrated.
YY1 binding to upstream HPV-16 silencer elements had little effect when each site was mutated individually in the context of the native P97 promoter. Simultaneous mutation of multiple distal YY1 sites, however, resulted in increased P97 transcription in vivo (Lace et al., 2009) . The distal YY1 cis elements may be regulated by YY1-mediated mechanisms distinct from that of the promoter (Inr) YY1-binding elements, perhaps by interference with transcription activators bound to the adjacent HPV-16 enhancer, while YY1 bound to the promoter-proximal sites targets the general transcription machinery directly via displacement or quenching. It is also possible that both mechanisms function alternately or cooperatively in the course of YY1-mediated downregulation of P97 transcription in the course of the virus life cycle and that additional YY1-binding sites not defined in this study may also contribute to this effect.
Mechanisms of YY1 repression
YY1 repression, or activation, of viral and cellular promoters may involve a multicomponent mechanism . YY1 has been shown to interact with a promoter-proximal Sp1 (Lee et al., 1993; Seto et al., 1993) and the TBP-associated factor, TAF(II)55, in vitro (Martinez et al., 1994) , indicating that it may disrupt promoter activation by cellular transactivators and/or inhibit the assembly or function of the general transcription machinery itself. These observations may be particu- (Licht et al., 1993) . Such selectivity of YY1 interaction with other factors could introduce an additional level of complexity to the mechanisms of YY1 repression. The Drosophila Krüppel protein also appears to shift from an activator to a repressor of TFIIB-mediated activity in a concentration-dependent manner as it begins to form dimers at higher concentrations (Sauer & Jäckle, 1993) . No such concentration-dependent shift in YY1 function, however, has been demonstrated. Post-translational modification of the YY1 protein by phosphorylation or acetylation also appears to provide additional modulation of its function (Yao et al., 2001 ).
The YY1-mediated downregulation of HPV-16 transcription, as well as other promoters, may be modulated further by interactions between YY1 and other secondary proteins. YY1 complexed with LSF (late SV40 transcription factor) can recruit histone deacetylase to repress transcription from the human immunodeficiency virus type 1LTR (Coull et al., 2000) . YY1 has also been shown to recruit histone methyl transferases, such as the H4-specific PRMT1, to a YY1-activated promoter to influence its activity, presumably through chromatin remodelling (Rezai-Zadeh et al., 2003) . Furthermore, YY1 appears to play a role in cell cycle-dependent gene expression through nuclear localization of existing pools of YY1 protein prior to G1/S phase (Palko et al., 2004) . The adenovirus E1a transforming protein has been shown to convert YY1 from a repressor into an activator Lewis et al., 1995) via interaction with a YY1-p300 complex (Lee et al., 1995) . The addition of p300 relieved YY1-mediated repression when E1a was present and this effect was dependent on two distinct p300 domains necessary for protein-protein interaction with E1a and YY1, respectively. As E1a and the HPV-16 E7 proteins share significant sequence similarities and functional properties, one would predict the same effect on YY1-mediated repression with increasing levels of E7. In transient-transfection CAT assays performed in HPV E6-and E7-negative cell lines, however, we observed no relief of YY1-mediated repression of upstream HPV-16 reporters upon addition of HPV-16 E7 or E1a expression plasmids, whilst the Ad E1a and HPV-16 E7-responsive control (Ad E2 cat) was activated by both E7 and AdE1a cotransfection in parallel, indicating expression of functional levels of each protein in these experiments (data not shown).
Whilst we have found that the trans-activation domain of the viral E2 protein can cooperate with YY1 to activate transcription from a heterologous minimal promoter in CAT assays (data not shown), we have not seen an E2-dependent reversal of YY1 downregulation of the HPV-16 E6-E7 promoter in our assays. In fact, in transcription assays, where functional endogenous levels of the HPV-16 E2 protein are expressed from the intact viral genome, YY1 continues to downregulate the E6-E7 promoter effectively in vivo (this study).
Additional examples of protein-protein interactions potentiating YY1 function include the c-Myc protein, which appears to contact YY1, inhibiting both the positive and negative YY1 functions at the AAV P5 promoter (Shrivastava et al., 1993) . A related example of this phenomenon has been documented with the human thyroid hormone receptor (hTRbeta), which is also converted from a repressor to an activator upon complexation with its thyroid hormone ligand (Roberts & Green, 1995) . Similar effects on YY1 function were also demonstrated by association with the murine nucleolar phosphoprotein B23 (Inouye & Seto, 1994) . Nuclear matrix protein 1 has also been identified as YY1 (Guo et al., 1995) , suggesting that YY1 also interacts selectively with matrix-associated transcription factors, such as E1a and c-Myc, by compartmentalization of YY1-bound promoters and potentially providing an additional layer of YY1-dependent gene regulation.
YY1 functions as a downregulator, not an initiator, of HPV-16 early transcription at the P97 start site
In our examination of the promoter-proximal YY1 site in HPV-16, three independent overlapping nucleotide-substitution mutations in the Inr I YY1 site relieved YY1-mediated downregulation of the P97 promoter and abolished YY1 binding; this result argues against the possibility of generation of a novel binding site for a positive cis-acting factor or disruption of an existing cisactivator-binding site in our experiments.
Nucleotide-substitution mutagenesis of the P97 start site has identified nucleotides that are required for YY1 binding and YY1-mediated inhibition of P97 transcription, but not required for correct initiation of P97 transcripts. These results demonstrate clearly that YY1 is not an 'initiator' factor at the P97 promoter and that mutual competition between YY1, as a transcriptional inhibitor binding to the Inr I site, and an additional 'initiator' factor(s) binding at or near the P97 transcription start site results in downregulation of P97 transcription. These results do not rule out the potential contribution of additional cellular factors, binding to cis elements in the HPV-16 promoter, in negatively potentiating P97 transcription independently or in cooperation with YY1. Interestingly, although the HPV-16 URR is composed of a complex array of cis elements that can regulate multiple virus functions, mutation of the P97-proximal YY1 site relieved transcription from this major early promoter, but did not influence plasmid replication. This demonstrates that YY1 primarily modulates E6-E7 expression when bound to the P97 promoter start site without affecting other critical early virus functions. Further studies into the mechanisms of YY1-mediated downregulation of HPV-16 gene expression would include the identification of (i) initiator-like factors binding near HPV promoter start sites as potential targets for YY1-mediated displacement, and (ii) additional viral or cellular secondary proteins interacting with YY1 and the role of these mechanisms in establishing and maintaining persistent papillomaviral infection.
In conclusion, YY1 continues to emerge as a critical component in the regulation of virus functions necessary for establishment and persistence of HPV infection, including early gene transcription. This study underscores the expanding inventory of diverse strategies employed by DNA tumour viruses such as HPV and AAV that have evolved to use the same cellular factors, for example YY1, to achieve distinct modulation of critical early viral gene expression.
